EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19 (MERMAIDS 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04364711|
Recruitment Status : Unknown
Verified April 2020 by MJM Bonten, UMC Utrecht.
Recruitment status was: Not yet recruiting
First Posted : April 28, 2020
Last Update Posted : April 28, 2020
Background Rapid European COVID-19 Emergency Research response (RECoVER), is a project involving 10 international partners that has been selected for funding by the European Union under the Horizon 2020 research framework responding to call topic SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the SARS-CoV-2 epidemic. MERMAIDS 2.0 is the hospital care study within RECOVER.
Rationale Detailed patient-oriented studies are needed to determine the spectrum of SARS-CoV-2 disease and the combined influences of age, comorbidities and pathogen co-infections on the development of severe disease, together with virological and immunological profiles. This research is key to understanding the pathophysiology and epidemiology of this new disease, as well as to identifying potential targets for therapeutic or preventive interventions.
Objective To establish the prevalence, disease spectrum and severity, clinical features, risk factors, spread and outcomes of novel 2019 coronavirus infection (SARS-CoV-2) in Hospital Care.
Study design Prospective observational cohort study in selected European countries.
Children and adults with 1) acute respiratory illness (ARI) presenting to hospital care during the SARS-CoV-2 epidemic (including both COVID-19 and non-COVID-19 patients) and 2) patients with confirmed COVID-19 infection, but with atypical presentation (non-ARI) or with nosocomial acquisition. Sites can optionally participate in the following tiers:
Tier 0 (Clinical data collection only) - Clinical data will be collected but no biological samples will be obtained for research purposes. Summary of the illness episode and outcome, including a selection of risk factors and comorbidities and medications.
Tier 1 (Clinical data and biological sampling) - Clinical samples and data will be collected on enrolment day and then at scheduled time points.
Tier 2 (Clinical data an extended biological sampling).
Optional add-on study In a subset of sites and patients, COVID-19 positive patients will be followed post-discharge for 6 months to study clinical recovery and long-term sequelae Main study parameters/endpoints: Prevalence of COVID-19 among patients with acute respiratory illness. COVID-19 disease spectrum and host and pathogen risk factors for severity. Long-term sequelae of COVID-19 requiring hospital care. Proportion hospital-acquired COVID-19 infections and characteristics of nosocomial transmission.
Study Duration Scheduled 2 years and based on COVID-19 dynamics.
Nature and extent of the burden associated with participation, benefit and group relatedness This study is observational in nature. There will be no direct benefit to research participants. The study may include biological sampling in addition to sampling required for medical management. The results of the tests done on these samples may not contribute to improving the participant's health. Minimal inconvenience and discomfort to the participant may arise from study visits and biological sampling.
|Condition or disease|
|COVID-19 SARS-CoV 2|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Multi-centre EuRopean Study of MAjor Infectious Disease Syndromes (MERMAIDS) - Acute Respiratory Infections (MERMAIDS ARI) 2.0|
|Estimated Study Start Date :||May 1, 2020|
|Estimated Primary Completion Date :||April 30, 2022|
|Estimated Study Completion Date :||April 30, 2022|
- Pneumonia Severity indexes [ Time Frame: 2 years ]
- Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support [ Time Frame: 2 years ]
- Hospital - and ICU/HCU length of stay [ Time Frame: 2 years ]
- In-hospital mortality [ Time Frame: 2 years ]
- Activities of daily life, quality of life, variations in home living status and employment status [ Time Frame: 2 years ]
- Proportion of SARS-CoV2 positive patients [ Time Frame: 2 years ]